BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19275595)

  • 1. Peptides for tumour therapy and diagnosis: current status and future directions.
    Zaccaro L; Del Gatto A; Pedone C; Saviano M
    Curr Med Chem; 2009; 16(7):780-95. PubMed ID: 19275595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer.
    Okarvi SM
    Cancer Treat Rev; 2008 Feb; 34(1):13-26. PubMed ID: 17870245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
    Behr TM; Béhé MP
    Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiolabelled regulatory peptides for imaging and therapy.
    Breeman WA; Kwekkeboom DJ; de Blois E; de Jong M; Visser TJ; Krenning EP
    Anticancer Agents Med Chem; 2007 May; 7(3):345-57. PubMed ID: 17504160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and perspectives in peptide receptor radiation therapy.
    Ansquer C; Kraeber-Bodéré F; Chatal JF
    Curr Pharm Des; 2009; 15(21):2453-62. PubMed ID: 19601842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor-mediated tumor targeting with radiolabeled peptides: there is more to it than somatostatin analogs.
    Mariani G; Erba PA; Signore A
    J Nucl Med; 2006 Dec; 47(12):1904-7. PubMed ID: 17138731
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
    Behr TM; Béhé M; Becker W
    Q J Nucl Med; 1999 Sep; 43(3):268-80. PubMed ID: 10568142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candidates for peptide receptor radiotherapy today and in the future.
    Reubi JC; Mäcke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():67S-75S. PubMed ID: 15653654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.
    Reubi JC; Waser B
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):781-93. PubMed ID: 12707737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolabelled peptides for oncological diagnosis.
    Laverman P; Sosabowski JK; Boerman OC; Oyen WJ
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S78-92. PubMed ID: 22388627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for the use of radiolabelled peptides in diagnosis and therapy.
    Koopmans KP; Glaudemans AW
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S4-10. PubMed ID: 22388630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor radionuclide therapy of tumors: a road from basic research to clinical applications.
    Bodei L; Paganelli G; Mariani G
    J Nucl Med; 2006 Mar; 47(3):375-7. PubMed ID: 16513604
    [No Abstract]   [Full Text] [Related]  

  • 15. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.
    de Jong M; Kwekkeboom D; Valkema R; Krenning EP
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):463-9. PubMed ID: 12569416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
    Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
    J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-targeted delivery systems based on peptides.
    Chatzisideri T; Leonidis G; Sarli V
    Future Med Chem; 2018 Sep; 10(18):2201-2226. PubMed ID: 30043641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA; Papadogias D; Makras P; Grossman AB
    Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiolabelled peptides--promises and pitfalls.
    Mather SJ
    Nucl Med Commun; 2000 Jun; 21(6):507-9. PubMed ID: 10894558
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.